Psyadon Pharmaceuticals is dedicated to the discovery and development of new treatments for the serious psychiatric and neurological diseases. Ecopipam, our first development candidate, selectively blocks the actions of the neurotransmitter dopamine at the D1 subtype in the brain. This first-in-class compound has the potential to successfully help people who previously had no other therapeutic options.